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Abstract: The Nova Scotia Environmental Health Centre is a treatment facility for individuals 
with chronic environmental conditions such as multiple chemical sensitivity, chronic fatigue 
syndrome, ﬁ  bromyalgia, chronic respiratory conditions and in some cases chronic pain. The 
premise of care is to provide a patient-centred multidisciplinary care approach leading to self-
management strategies. In order to measure the outcome of the treatment in these complex prob-
lems, with overlapping diagnoses, symptoms in many body systems and suspected environmental 
triggers, a detailed symptoms questionnaire was developed speciﬁ  cally for this patient population 
and validated. Results from a pilot study in which an abbreviated symptoms questionnaire based 
on the top reported symptoms captured in previous research was used to measure the efﬁ  cacy of 
a multidisciplinary care approach in individuals with multiple chemical sensitivity are presented 
in this paper. The purpose of this study was to examine the extent, type and patterns of changes 
over time in the top reported symptoms with treatment measured using the abbreviated symptoms 
questionnaire. A total of 183 active and 109 discharged patients participated in the study where 
the health status was measured at different time periods of follow up since the commencement 
of treatment at the Centre. The ﬁ  ndings from this study were successful in generating an initial 
picture of the nature and type of changes in these symptoms. For instance, symptoms such as 
difﬁ  culty concentrating, sinus conditions and tiredness showed early improvement, within the 
ﬁ  rst 6 months of being in treatment, while others, such as fatigue, hoarseness or loss of voice, 
took longer while others showed inconsistent changes warranting further enquiry. A controlled 
longitudinal study is planned to conﬁ  rm the ﬁ  ndings of the pilot study.
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Introduction
Chronic environmental conditions are a growing concern and a signiﬁ  cant burden to 
the health care system due to the magnitude of the problem (Geertrudis and Van Den 
Bos 1995; Weiss and Sullivan 2001; Kipen and Fiedler 2002; Litt et al 2004; Druss 
et al 2001; Bowles 2006) and lack of efﬁ  cient and effective management strategies 
(Thea and Vliet 2004).
The Nova Scotia Environmental Health Centre (NSEHC) is a medical facility for 
treating chronic conditions with probable links to the environment, such as multiple 
chemical sensitivity (MCS), chronic fatigue syndrome (CFS), ﬁ  bromyalgia (FM) and 
other chronic conditions. The management of such conditions is a controversial subject 
with limited documentation or evidence of support for any particular approach (Litt 
et al 2004). For most of these conditions there are no speciﬁ  c guidelines to treatment 
that have been shown to reverse the condition (Hessl 1987; Ziem and McTamny 1997; 
Sparks 2000; Hoffres et al 2001). The complexity of these problems, with overlapping Journal of Multidisciplinary Healthcare 2008:1 98
Fox et al
diagnoses, symptoms in many body systems and suspected 
environmental triggers, often leave the medical practitioner 
bafﬂ  ed. From our experience of managing these patients 
we ﬁ  nd various contributors to impaired health, including 
physical, psychological, social and environmental factors 
affect the symptoms reported by patients. The relative con-
tributions of these factors may vary between patients or in 
individual patients over time. The complex interactions of 
these factors determine the severity of the symptoms and the 
overall clinical presentation. This understanding is crucial to 
the management of these patients where severe symptoms 
may exist in the absence of any objective physical or physi-
ologic ﬁ  ndings (Katon and Walker 1998). The management 
scheme thus requires the involvement of a multidisciplinary 
teamof clinicians in order to ensure that all aspects of the 
patient’s health are addressed.
Adopting a symptom-based, patient-centred and 
multidisciplinary care approach that encompasses all 
aspects of the patient’s health is the care model used in the 
management of the patients at the Centre. The crux of the 
treatment is in assisting the patient toward self-management 
by providing the necessary care, support and education. Our 
care model is in line with Health Canada’s 12 Determinants 
of Health (WHO) and the chronic model of care (Wagner 
et al 2001). The care provided at the Centre is individualistic 
and the care team comprises of a multidisciplinary team of 
clinicians (Pollard 2004) which includes a physician, nurse, 
physiotherapist, psychologist/psychotherapist, dietician and 
rehabilitation coordinator. The patient is actively engaged in 
the multidisciplinary team decisions and in the development 
of the individualized care plan through regular discussions 
with their care coordinator at the Centre, their physician. 
The care management scheme at the NSEHC is divided 
into speciﬁ  c phases of intervention to effectively assist the 
patient towards self management of their condition. The 
management begins with in-depth evaluation and patient 
education, a phase of passive and baseline intervention by the 
care providers, a phase of intervention with patient being an 
active participant, a phase of collaborative self management 
phase with the involvement of the care providers and 
concluding with self management by patients.
Care at the Centre begins with a comprehensive evaluation 
of the patient’s condition by the multidisciplinary care team. 
A variety of diagnostic tests including balance assessment 
using a sway tester, exposure testing in a controlled environ-
ment chamber, and psychodiagnostic by a psychologist are 
conducted during this phase. This information gathering phase 
also includes administering several validated questionnaires 
such as Symptoms Checklist Inventory (SCL-90R), 
Fibromyalgia Impact Questionnaire along with holding 
detailed interviews that cover a broad range of physical, 
psychological, social and environmental aspects of illness. 
Based on the outcome of the evaluation, some baseline 
education and information tools are offered to patients to 
enhance the understanding of their illness. As patients go 
through this phase, further tests and inquires regarding the 
health condition may be done by the health care team to obtain 
clarity about the patient’s illness. Preliminary intervention 
schemes that are generic in nature such as dietary interven-
tion, stress management, rehabilitation support, building 
physical and emotional resiliency may be offered while the 
patient speciﬁ  c care plan is being developed by the care 
team. As detailed aspects of a patient’s condition become 
evident, the care team generates an individualized care plan 
for the patient which involves a focused treatment approach 
that directly relates to the outstanding aspect of the patient’s 
illness which may be pain and fatigue management using a 
graded exercise therapy or addressing psychological symp-
toms with an emotion-focussed treatment approach. During 
this phase, the patient becomes an active participant of their 
care management. Tools and community integration schemes 
for self management are identiﬁ  ed for every patient during 
this phase and the care team collaboratively facilitates this 
change for a period of time with exit point of care being self 
management of the condition by the patient.
Treatment approaches offered to provide symptomatic relief 
include desensitization for classical allergies, physiotherapy 
for deconditioning, systemic and topical pharmaceutical agents 
for pain relief, intravenous nutrients for fatigue or relief of mus-
culo-skeletal pain, heat depuration (sauna) and exercise. In the 
absence of any therapy that is known to reverse the underlying 
condition, other individualized approaches are used to help 
patients manage their problems and achieve a higher level of 
health. Stress, environmental or emotional, is addressed with 
counselling, craniosacral therapy or guided imagery, and on 
a group basis with mindfulness based stress reduction, Well-
ness and FreezeFrame® programs. Environmental stress is also 
managed by reducing exposures. The treatment modalities are 
all designed to coach, educate and train the patients to use the 
techniques in the self management of their condition.
A study conducted at the Centre looked at the prevalence 
of major symptoms in 351 patients at the Centre. The 
major prevalent symptoms identiﬁ  ed by thestudy were 
displayed in multiple body systems. General symptoms 
such as difﬁ  culty concentrating, fatigue, forgetfulness, and 
irritability were found to be present from the start of illness. Journal of Multidisciplinary Healthcare 2008:1 99
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Those related to irritation such as congested sinuses, itchy 
or burning eyes, and hoarseness or loss of voice were more 
common after exposure to environmental irritants (Joffres 
et al 2001).
Since the symptoms displayed by the patients affect 
multiple body systems, it was deemed important to develop 
a tool that measured and captured the changes in all of 
the body systems. A detailed questionnaire based on the 
Toronto Health Survey questionnaire (McKeown-Eyssen 
et al 1994) was developed and validated for use at the Centre 
on individuals with chronic environmental conditions. This 
questionnaire contains modifications from the original 
version based on feedback to the Toronto investigators, 
from focus groups involving patients, practitioners and pilot 
testing. Changes to original questionnaire included reducing 
the length of the questionnaire by adding more open-ended 
questions to capture perceived provocation of symptoms 
related to exposures. The language of the questionnaire was 
simpliﬁ  ed and made politically sensitive. A general health 
section covered patients’ health status since the beginning 
of their illness. The next section focussed on limitations 
in their daily activities due to their illness and a section on 
health problems documented major conditions diagnosed by 
a physician. The section on symptoms addressed symptoms 
that the patients may have experienced since the start of their 
illness, frequency and intensity, and whether or not these 
symptoms occurred or got worse after identiﬁ  ed exposure. 
Open-ended questions provided space for patients to list 
the type of exposures that might have been associated with 
occurrence of their symptoms. This was followed by their 
family history, demographic characteristics, employment 
history, socio-economic status and information related to 
the completion of the questionnaire. A validation study was 
conducted to determine the effectiveness and the sensitivity 
of the NSEHC symptoms questionnaire. The study examined 
the prevalence of 217 symptoms in 13 sections/systems. It 
was the ﬁ  rst attempt to describe the type, frequency, and 
severity of the most common symptoms experienced by an 
environmentally sensitive population. A total of 385 (47%) 
questionnaires were returned, and data were analyzed on 
351 individuals. Participants tended to be women (80%), 
middle-aged individuals (37% age 40–49 years), and those 
in higher educational groups (28% completed university), 
but there was wide variation in demographic variables. The 
results from this study helped generate the top symptoms that 
were prevalent in this patient population. General symptoms 
such as difﬁ  culty concentrating, fatigue, forgetfulness, and 
irritability dominated the overall prevalence of symptoms 
since the start of their illness. Those related to irritation such 
as sneezing, itchy or burning eyes, and hoarseness or loss of 
voice were more common after exposure to environmental 
irritants. Ranking of symptoms using severity scores was 
consistent between men and women. Overall scores were 
higher in women, in participants who were separated or 
divorced, and in low-income groups. The top 15 symptoms 
reported in this study following an exposure are as shown 
in Table 1.
As a follow up to this study, another study was conducted 
to evaluate the impact of a multidisciplinary treatment 
approach on the top reported symptoms in the patient 
population. The results from this pilot study are reported in 
this paper. The abbreviated version of the NSEHC symptoms 
questionnaire, NSEHC-BREF was created to capture the 
changes in the top reported symptoms over various time 
periods of follow up since the commencement of treatment 
at the Centre. In the NSEHC-BREF, an introductory overall 
health related question and an open-ended question at the 
end used to capture any other incidents or changes that may 
have impacted the health status were also used. The sections 
on family history, demographic characteristics, employment 
history, socio-economic status and information related to the 
Table 1 Prevalence of the top 15 symptoms reported since the 
start of the illness and ranked by sex in individuals with MCS 
following an exposure
Symptoms Males
N = 70%
Females
N = 281%
Sneezing/runny or congested
nose without a cold
60 68
Itchy eyes 59 65
Difﬁ  culty concentrating 47 56
Other headache 41 54
Burning eyes 46 52
Hoarse of loss of voice 29 54
Stuffy or full sinuses 44 47
Forgetfulness/poor memory 33 49
Tight chest 34 48
Usually acceptable odors were
sickening
41 45
Fatigue, very tired, without energy 40 44
Difﬁ  culty making decisions 34 45
Trouble ﬁ  nding the right words 31 46
Irritability 43 43
Feeling light-headed 37 44
% indicates percent of patient having the symptom.Journal of Multidisciplinary Healthcare 2008:1 100
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completion of the questionnaire were excluded since these 
changes are captured in the multidisciplinary interviews and 
in the main symptoms questionnaire. The NSEHC-BREF is 
seen as more of a follow up tool to measure the impact of 
treatment on the top reported symptoms. The idea around 
capturing changes in these speciﬁ  c symptoms related to 
exposure is to study the degree of symptoms management 
achieved with treatment in individuals with MCS. Thus the 
overall objective of this study was to examine the type and 
extent of changes observed in the top reported symptoms as 
an outcome of the multidisciplinary treatment over various 
time periods of follow up. The scores from NSEHC-BREF 
were compared to the scores measured using the main 
symptoms questionnaire.
Methods
Subject selection and recruitment
Approximately 500 patients with a diagnosis of MCS (Bartha 
et al 1999) in combination with CFS or FM were approached 
for participation. Patients were selected under the following 
categories: 6 month to 1 year of treatment at the Centre, 
1 to 2 years of treatment at the Centre, 2+ years to a maximum 
of 5 years of treatment at the Centre and discharged patients. 
A total of 183 active patients participated in the study 
under the following categories: 6 months to 1 year of treat-
ment at the Centre, 1 to 2 years of treatment at the Centre, 
2+ to a maximum of 5 years of treatment at the Centre and 
109 discharged patients. Patients who agreed to participate 
were mailed out the abbreviated questionnaire along with 
the consent form.
Outcome measure and data analyses
The Nova Scotia Environmental Health Centre abbrevi-
ated symptoms questionnaire, NSEHC-BREF was used to 
monitor changes in health over various time periods after 
enrolment to the Centre.
The symptom scores were computed as the frequency 
of occurrence of symptoms 7 days prior to their ﬁ  lling out 
the NSEHC-BREF (rarely, from time to time, most of the 
time, all the time, rated as 1–4) multiplied by the severity 
(low, moderate, high, rated 1–3). Therefore the maximum 
score for each question is 12, the minimum being 0. The 
global score is a mean score computed as the sum of all 
scores divided by the number of symptoms. Comparison 
of symptom scores from the NSEHC-BREF was made 
against the detailed questionnaire scores that have already 
been computed for each patient at the Centre. SAS 9.1 
was used to conduct the statistical analysis for the study. 
There are 30 questions in total in the NSEHC-BREF with 
22 questions on symptoms and 8 questions on the overall 
health. The time required to complete the questionnaire is 
approximately 15 minutes.
The Capital District Health Authority Research Ethics 
Board approved this study.
Results
A total of 183 active patients and 109 discharged 
patients participated in the study. About 250 active 
patients and 250 discharged patients were approached for 
participation.
Table 2 shows the demographical details for the subjects 
who participated in the study. The response rate from the 
female participants was higher than the male participants.
Table 3 shows the overall improvement in health in 
the different groups of patients tested. Patients showed 
statistically signiﬁ  cant improvement in their overall health 
under categories such as health since ill 0.05 (6 months–
1 year), 0.0001 (1–2 years, 2+ years, discharged); 
too ill to do housework 0.05 (6 months–1year), 0.008 
(1–2 years), 0.0001 (2+ and discharged); limit contact 
with people to avoid exposures 0.9 (6 months–1 year), 0.09 
(1–2 years ), 0.02 (2+ years ) and 0.0001 (discharged).
Tables 4 and 5 show changes in symptoms grouped under 
different categories. Table 4 captures changes observed in 
eyes, nose, throat and respiratory symptoms. Stronger sense 
of smell and tight chest showed consistent and early changes 
of statistical significance with 0.02 (6 months–1 year), 
0.008 (1–2 years), 0.001 (2+ and discharged) and 0.03 
(6 months–1 year), 0.0007 (1–2 years ), 0.0001 (2+) and 
0.02 (discharged) respectively. Nose symptoms such as 
usually acceptable odors were sickening and stuffy or full 
sinuses were observed in the 1 year and above groups. Hoarse 
of loss of voice and itchy eyes showed sudden improvements 
in 2+ and discharged groups.
Table 5 shows changes in health measured in blood 
and gland, nervous system and muscle and joints. Symp-
toms showing consistently signiﬁ  cant improvement in 
various time periods of follow up include Symptoms 
such as difﬁ  culty concentrating 0.01 (6 months–1 year), 
0.003 (1–2 years) and 0.0001 (2+ and discharged); dif-
ﬁ  culty making decisions 0.007 (6 months–1 year), 0.002 
(1–2 years) and 0.0001 (2+ and discharged); tiredness 
not relieved by sleep 0.002 (6 months–1 year), 0.01 (1–2 
years ) and 0.0001 (2+ and discharged); and muscle 
spasms and cramps 0.02 (6 months–1 year), 0.002 (1–2 
years ), and 0.002 (2+ years and discharged). Symptoms Journal of Multidisciplinary Healthcare 2008:1 101
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such as irritability, forgetfulness and trouble ﬁ  nding the 
right words showed signiﬁ  cant changes in the groups past 
1 year of treatment. Fatigue and tiredness without energy 
showed sudden improvements in 2+ and discharged groups. 
Inconsistent changes were observed in categories such as 
bruise easily, muscle pain and sensitive to temperature 
changes.
Discussion
The prevalence of unexplained symptoms and reactivity is 
on the increase in the recent years (Caress and Steinemann 
2004). Many patients of the Centre have spent several years 
trying to ﬁ  nd the right clinicians who can understand their 
illness and help them manage it (Geertrudis and Van Den 
Bos 1995; Druss et al 2001). When they are ﬁ  rst seen at the 
Centre, patients often present a very negative perspective of 
the health system and are very dysfunctional on account of 
their existing symptoms.
Measuring changes in chronic health conditions such 
as MCS is often challenging with patients having multiple 
diagnoses and multiple care providers. The goal of 
multidisciplinary care approach at the Centre is to provide 
an individualized care approach for its patients with timely 
evaluation of the presenting symptoms and integrated 
care delivery by multidisciplinary care providers. Black 
et al (2000) have described the possible effects of time 
over treatment in a 9-year follow up study of individuals 
with MCS. However, it is important to identify the type of 
symptoms that change and the extent of these changes if we 
are to determine whether it is the treatment or simply the 
passage of time that contributes to improvements in health. 
If there are positive changes in health, then a qualitative 
study can clarify the potential reasons for these changes. 
It is also challenging to identify any one treatment that 
may have had an impact on the improvement in health 
symptoms (Rundall et al 2002; Richardson and Engel 
2004). It may be a combination of treatments in addition 
to education and lifestyle changes that is impacting the 
health of an individual. The objective of this study was to 
quantify the effects of an integrated care approach in the 
Table 2 Demographics
Active N = 182 Discharged N = 109
Periods of time 
follow up
6 month-
1 year
1–2 years 2+ years 6 month-
3 years
3–5 years 5+ years Total
Age
Mean (SD) 47.3 (10.3) 48.5 (8.7) 50.8 (10.5) 54.7 (10.7) 52.8 (10) 52.7 (12.3) 53.3 (10.8)
Range 25–62 30–64 18–74 30–75 19–75 19–78 19–78
Sex Number of Participants
Male 1 0 20 5 5 7 17
Female 31 32 99 22 44 25 92
Table 3 Changes measured in overall health
Period of time
follow up
6 m–1 year* (n = 32) 1–2 years (n = 32) 2+ years (n = 118) Discharged (n = 109)
Pre
Mean
(SD) 
Post
Mean
(SD)
p-value Pre
Mean
(SD) 
Post
Mean
(SD)
p-value Pre
Mean
(SD) 
Post
Mean
(SD)
p-value Pre
Mean
(SD) 
Post
Mean
(SD)
p-value
Health since
ill
3.03
(1.1) 
3.59
(1.4)
0.05 2.63 
(1.3) 
4.18
(1.5)
0.0001 2.6 
(1.1) 
3.9
(1.4)
0.0001 2.94 
(1.3) 
4.29 
(1.3)
0.0001
Limit contact 2.9 3.03 0.9 3.5 3.1 0.09 3.5 3.3 0.02 3.4  2.7 0.0001
with people to
avoid exposures
(1.1) (1.2) (1.1) (1.2) (1.1) (1.2) (1.1) (1.3)
Too ill to do
housework
3.2
(0.9) 
2.8
(1.01)
0.05 3.2  
(0.7) 
2.4
(1.1)
0.0008 3.5
(0.8) 
2.9
(1.01)
0.0001 3.2 
(0.7) 
2.5 
(1.1)
0.0001
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MCS population regardless of the type of individualized 
care prescribed to the patient.
The pilot study has helped us identify a useful tool that 
will allow us to measure health changes in patients with MCS. 
The abbreviated questionnaire was used to focus the attention 
on the nature and extent of changes in the top reported symp-
toms in the MCS group. The results are promising evidence of 
the effectiveness of the NSEHC-BREF in measuring changes 
at various time periods of follow up.
The pilot study showed some interesting changes in 
the top reported symptoms in various categories and at 
various time periods of follow up. Some changes were 
more consistent than others. Observed changes in nose and 
nervous systems such as improvement in stuffy sinuses 
and concentration match our clinical observations. Some 
of the inconsistencies in bruise easily and sensitivity to 
temperature changes raise questions on being captured as 
top symptoms related to exposures in this sensitive popula-
tion in our previous research. This study has provided some 
preliminary results on the nature and extent of symptom 
changes in MCS using an abbreviated questionnaire. This 
study has also shown that there may be beneﬁ  ts in con-
sidering a more comprehensive approach to treating these 
individuals displaying symptoms in multiple body systems 
rather than a rigid treatment protocol that either treats the 
physical or the psychological symptoms. The study does 
have its limitation which needs to be addressed in order to 
draw more meaningful conclusions.
Limitations
There were limitations to the study design in which the 
primary objective was to evaluate the effectiveness an 
abbreviated symptoms questionnaire in measuring changes in 
health related to a multidisciplinary treatment approach. The 
study was neither randomized nor longitudinal in design. So, 
while it is interesting to observe the type of symptoms that 
changed and reached statistical signiﬁ  cance, it is impossible 
to comment beyond that since the same individuals were not 
followed at the different time periods. It is also crucial to have 
controls in the study in order to determine the impact of pas-
sage of time in the observed improvements in health.
Conclusions
Despite the study limitations, the pilot was a useful ﬁ  rst step 
to observe the changes in health in MCS patients undergoing 
a multidisciplinary care approach with the abbreviated 
symptoms questionnaire. The study helped identify an 
outcome tool that measures the overall effect of treatment 
over a period of time rather than trying to identify or isolate 
the effects of a particular treatment. The outcome of this 
Table 4 Changes measured in eyes, nose, throat symptoms and respiratory systems
Period of time 
follow up
6 m–1year* (n = 32) 1–2 years (n = 32) 2+ years (n = 118) Discharged (n = 109)
Pre
Mean 
(SD) 
Post
Mean
(SD)
p-value Pre 
Mean 
(SD) 
Post
Mean
(SD)
p-value Pre
Mean 
(SD)
Post
Mean
(SD)
p-value Pre
Mean
(SD) 
Post
Mean
(SD)
p-value
Burning eyes 2.4 
(3.3)
1.9
(2.5)
0.06 2.8
(3.2)
2.5
(3.4)
0.4 3.4
(3) 
2.4
(2.8)
0.05 3
(2.4) 
1.7
(2.3)
Itchy eyes 2.2
(2.9) 
2.3
(2.9)
0.8 2.7
(2.7)
2.8
(2.7)
0.9 3.6
(2.5)
2.5
(2.5)
0.0001 3.5
(2.2) 
2.3
(2.7)
0.0001
Stuffy or full 4.7  4.3 0.7 5.2 2.9 0.006 4.8 3.1 0.0001 4.7 3.7 0.01
sinuses (3.6) (3.7) (4.1) (3.4) (3) (2.9) (3.2) (2.9)
Sneezing/runny nose 
without a cold
5.5
(4.6) 
3.0
(3.6)
0.001 7
(5)
4.3
(5)
0.006 5.1
(3.6) 
3.1
(3.5)
0.0001 4.2
(3.4) 
3.5
(3.5)
0.1
Stronger sense of smell 4.5
(4.9) 
2.3
(3.4)
0.02 6.5
(5.7)
3.2
(4.1)
0.008 7.2
(4.6)
3.1
(3.7)
0.0001 6.6
(4.8) 
3.4
(4.2)
0.0001
Usually acceptable 
odors were sickening
4.7
(3.8) 
3.9
(3)
0.34 4.9
(3.7)
3.4
(3.1)
0.09 5.4
(3.9)
2.8
(3)
0.0001 4.5
(4.1) 
2.4
(3.6)
0.0001
Tight chest 2.4
(2.4) 
1.2
(1.6)
0.03 4.3
(3.7)
2.2
(3.1)
0.0007 3.4
(2.9)
2.2
(2.8)
0.0001 2.8
(2.6) 
1.9
(2.6)
0.02
Hoarse or loss of voice 2.7
(3.2) 
2.8
(3.7)
0.8 3.1
(3.8)
2.6
(3.5)
0.5 3.9
(3.4)
2.8
(3.4)
0.0001 3.9
(3.3) 
2.2
(2.7)
0.0001
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Table 5 Changes measured in blood/gland, muscle joint and nervous system
Period of time 
follow up
6 m–1year (n = 32) 1–2 years (n = 32) 2+ years (n = 118) Discharged (n = 109)
Pre
Mean
(SD)
Post
Mean
(SD) 
p-value Pre
Mean
(SD) 
Post
Mean 
(SD)
p-value Pre
Mean
(SD)
Post
Mean
(SD)
p-value Pre
Mean
(SD)
Post
Mean
(SD)
p-value
Difﬁ  culty 
concentrating
4
(3)
2.0
(3.2)
0.01 5.5
(4.4)
2.4
(3.3)
0.0003 6.7
(3.2)
3.2
(3.6)
0.0001 6.2
(3.4)
3.8
(3.4)
0.0001
Difﬁ  culty making 
decisions
3.9
(3.9)
2.3
(3.1)
0.007 5.1
(4.1)
2.3
(3.1)
0.002 5.6
(3.7)
2.8
(3.2)
0.0001 4.5
(3.6)
2.2
(2.7)
0.0001
Trouble ﬁ  nding 
the right words
4.1
(3.4)
4.7
(3.5)
0.44 5.8
(4.4)
3.8
(3.9)
0.07 5.7
(3.7)
4.0
(3.7)
0.0001 5.0
(3.5)
3
(3)
0.0001
Forgetfulness/poor 
memory
3.7
(3.5)
2.7
(2.9)
0.14 4.6
(4.0)
2.2
(2.8)
0.004 6.4
(3.5)
3.1
(3.3)
0.0001 6
(3.8)
4
(3.4)
0.0001
Feeling light headed 4.1
(3.2)
2.9
(3)
0.06 4.3
(3.2)
2.4
(3)
0.01 4.3
(2.8)
3.0
(3.0)
0.08 3.1
(3)
2.1
(2.7)
0.003
Irritability 3.6
(3.4)
2.7
(2.8)
0.3 3.5
(3.6)
1.7
(2.1)
0.01 4.6
(2.9)
2.8
(2.8)
0.0001 4.5
(3.2)
2.6
(2.5)
0.0001
Bruise easily 5.7
(4.2)
5.3
(4)
0.6 5.9
(4.5)
4.1
(4.4)
0.1 4.1
(3.8)
4.2
(4)
0.9 4.1
(4)
2.8
(3.6)
0.01
Tiredness not 
relieved by rest/sleep
6.1
(4.2)
3.2
(3.5)
0.002 7
(4.6)
5.1
(4.3)
0.01 7.7
(3.8)
4.8
(4.5)
0.0001 6.7
(3.5)
4.3
(3.3)
0.0001
Sensitive to tempera-
ture change
6.7
(4.4)
3.5
(3.7)
0.0003 6.5
(4.3)
4.6
(4.4)
0.1 5.6
(4.4)
4.1
(4.1)
0.004 3.5
(3.8)
4.4
(4)
0.2
Fatigue, very tired, 
without energy
5.2
(3.5)
4.7
(4.5)
0.5 6.2
(4.6)
5.6
(4.2)
0.3 7.6
(3.7)
5.1
(3.9)
0.0001 6.5
(3.4)
4.8
(3.3)
0.0001
Muscle pain or ache 
not related to over 
exercise
3.7
(3.6)
3
(3.4)
0.5 5.1
(4.6)
3.7
(3.5)
0.09 5.5
(4.2)
4.5
(4.3)
0.02 4.6
(3.8)
4.6
(3.8)
0.9
Muscle spasms/
cramps
4.5
(3.5)
2.5
(4.3)
0.02 3.8
(4.8)
1.8
(3.6)
0.002 3.9
(3.3)
2.7
(3.3)
0.002 3.3
(3.3)
2.3
(3.3)
0.002
study clearly warrants further research into the efﬁ  cacy of 
the multidisciplinary approach in MCS in a longitudinal and 
randomized study design.
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